# Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults

> **NCT02246998** · PHASE4 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 72 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** STB
- **DRUG:** TVD
- **DRUG:** ATR
- **DRUG:** RTV
- **DRUG:** ATV
- **DRUG:** ABC/3TC
- **DRUG:** Iohexol

## Key facts

- **NCT ID:** NCT02246998
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-15
- **Primary completion:** 2016-01-20
- **Final completion:** 2016-02-17
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2018-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02246998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02246998, "Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults". Retrieved via AI Analytics 2026-07-23 from https://api.ai-analytics.org/clinical/NCT02246998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*